RESOURCES FOR YOU

 
Pocket Guide Image

POCKET GUIDE

Key facts about
SHINGRIX

Administration Reference Guide Image

ADMINISTRATION REFERENCE GUIDE

Storage, reconstitution,
and administration of
SHINGRIX

CDC Recommendation Guide Image

2018 CDC RECOMMENDATIONS SUMMARY

Summary of recommendations by the Advisory Committee on Immunization Practices (adopted
by the CDC)

Ordering Information Guide Image

ORDERING INFORMATION GUIDE

Packaging information and insurance coding
details for SHINGRIX

Implementation Guide Image

IMPLEMENTATION GUIDE

Dosing, administration, billing, and
reconstitution information for SHINGRIX

Chat Icon Learn more about SHINGRIX by attending a webinar. Sign up today!

RESOURCES FOR YOUR PATIENTS

What To Expect Guide Image

WHAT TO EXPECT

Everything your patients should know when
receiving SHINGRIX

 
Second Dose Reminder Card Image

SECOND DOSE REMINDER CARD

Provide your patients a reminder card for their
follow-up visit


Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
  • Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
  • SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

All trademarks are the property of their respective owners.

1005666R0 June 2018